We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,451.00
Bid: 1,451.00
Ask: 1,454.00
Change: -12.00 (-0.82%)
Spread: 3.00 (0.207%)
Open: 1,450.00
High: 1,461.00
Low: 1,440.00
Prev. Close: 1,463.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Indivior to Participate in Conference

20 May 2020 14:00

RNS Number : 5129N
Indivior PLC
20 May 2020
 

 

 

Indivior to Participate in Jefferies Virtual Healthcare Conference

Slough, UK and Richmond, VA - May 20, 2020 - Indivior PLC (LON: INDV) today announced that Shaun Thaxter, Chief Executive Officer, and Mark Crossley, Chief Financial & Operations Officer, will participate in the Jefferies Virtual Healthcare Conference on June 2, 2020. Please contact your Jefferies representative to request a meeting.

 

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. Our vision is for all patients around the world to have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. 

 

Contact:

Jason Thompson

804-402-7123

Vice President, Investor Relations

jason.thompson@indivior.com

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAASEADPEEFA
Date   Source Headline
20th Nov 20233:33 pmRNSDirector/PDMR Shareholding
20th Nov 20232:55 pmRNSIndivior to Participate in Upcoming Investor Event
20th Nov 202312:56 pmRNSDirector/PDMR Shareholding
20th Nov 20239:37 amRNSHolding(s) in Company
17th Nov 202311:37 amRNSShare Repurchase Program
17th Nov 202310:00 amRNSHolding(s) in Company
17th Nov 20239:59 amRNSHolding(s) in Company
17th Nov 20237:00 amRNSAmendment to Relationship Agreement with Scopia
16th Nov 20232:00 pmRNSIndivior to Participate in Upcoming Conference
15th Nov 20232:54 pmRNSHolding(s) in Company
15th Nov 202310:23 amRNSHolding(s) in Company
10th Nov 202310:17 amRNSBlock listing Interim Review
9th Nov 20237:01 amRNSAppointment of Independent Non-Executive Director
9th Nov 20237:00 amRNS3rd Quarter Results
1st Nov 20234:00 pmRNSIndivior to Participate in Upcoming Conference
26th Oct 202311:51 amRNSHolding(s) in Company
23rd Oct 20237:00 amRNSIndivior settles Antitrust MDL with DPs
13th Oct 202312:14 pmRNSHolding(s) in Company
5th Oct 20233:30 pmRNSNotice of Results
21st Aug 20237:00 amRNSIndivior settles Antitrust MDL with End Payors
1st Aug 20234:00 pmRNSTotal Voting Rights
27th Jul 20237:00 amRNSHalf-year Report
26th Jul 20234:00 pmRNSHolding(s) in Company
24th Jul 20234:00 pmRNSHolding(s) in Company
10th Jul 20234:00 pmRNSHolding(s) in Company
5th Jul 20234:00 pmRNSHolding(s) in Company
30th Jun 20234:00 pmRNSDirector Declaration
29th Jun 20234:00 pmRNSHolding(s) in Company
27th Jun 202311:00 amRNSNotice of Results
21st Jun 20234:00 pmRNSHolding(s) in Company
16th Jun 20234:00 pmRNSHolding(s) in Company
15th Jun 20234:00 pmRNSHolding(s) in Company
14th Jun 20234:00 pmRNSHolding(s) in Company
14th Jun 20234:00 pmRNSHolding(s) in Company
13th Jun 20234:00 pmRNSHolding(s) in Company
12th Jun 20237:00 amRNSIndivior to Commence Trading on Nasdaq
7th Jun 20233:45 pmRNSHolding(s) in Company
2nd Jun 20235:17 pmRNSIndivior settles antitrust MDL with states and DC
1st Jun 20239:11 amRNSTotal Voting Rights
26th May 20234:20 pmRNSHolding(s) in Company
25th May 20232:30 pmRNSIndivior to Participate in Upcoming Conferences
24th May 20233:05 pmRNSHolding(s) in Company
23rd May 20236:05 pmRNSIndivior Files Form 20-F for US Listing
23rd May 20232:42 pmRNSHolding(s) in Company
23rd May 20238:30 amRNSHolding(s) in Company
23rd May 20237:00 amRNSUS FDA Approves OPVEE
12th May 20232:56 pmRNSHolding(s) in Company
10th May 20233:30 pmRNSDirector/PDMR Shareholding
10th May 202312:00 pmRNSBlock listing Interim Review
10th May 20238:51 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.